| Study | Reason for exclusion |
|---|---|
| Boeer 1991 | This is an extension phase of Dickmann 1988 that introduces non‐randomised data to the previously published data |
| CAST 1997 | This trial included some people with ICH who were randomised prior to CT. These data were not available in the original manuscript. We had hoped that there would be useable data published in the Keir 2002 systematic review, but this did not separate spontaneous ICH from haemorrhagic transformations of acute ischaemic stroke and we were therefore unable to include data from CAST 1997 in this review |
| ChiCTR2000040166 | This is an ongoing randomised controlled study included patients with cerebral haemorrhage. The two intervention groups are traditional Chinese medicines, Musk huayu Xingnao and Vermiculus huoxue Tong yu granules, which are not proven to have an antithrombotic effect. We excluded the trial because the intervention was not an antithrombotic drug |
| Frontera 2014 | This is a controlled clinical trial that was not randomised |
| IST 1997 | This trial included several hundred participants with ICH who were randomised prior to CT. These data were not available in the original manuscript. We had hoped that data from the Keir 2002 systematic review or the published individual data forms (Sandercock 2011) would yield useable data for this review, but Keir 2002 did not report spontaneous ICH separately from haemorrhagic expansion of an acute ischaemic stroke, and after contacting the chief investigator of IST 1997 we discovered that it was not possible to extract data on spontaneous ICH separately |
| Kuramatsu 2018 | This study used data from an observational study, German‐wide multicenter analysis of oral anticoagulation associated intracerebral haemorrhage (RETRACE). The study was excluded because it was not randomised |
| Li 2013 | The intervention randomised in this study is transfusion of frozen apheresis platelets in participants on aspirin and with ICH, not an antithrombotic drug |
| RESTART extended follow‐up | This study reported extended follow‐up of the RESTART trial cohort, first reported in 2019. Patients were aware of their treatment allocation throughout, and were aware of the results of the main report of the trial when undergoing extended follow‐up. Therefore, there was more opportunity for bias in this open trial, arising from awareness of the main results during extended follow‐up, so we included RESTART 2019 in preference to this |
| Venturelli 2014 | This is a post‐hoc analysis of the INTERACT2 trial. The intervention that is the subject of this analysis, prophylactic subcutaneous heparin after ICH, was not randomly assigned in INTERACT2. Therefore, this analysis is observational in nature |
| Yan 2014 | The participant group did not have spontaneous ICH; it was a cohort of people with and without cerebral microbleeds and haemorrhagic transformation, with acute ischaemic stroke following rtPA treatment |
CT: computed tomography ICH: intracerebral haemorrhage rtPA: Recombinant tissue plasminogen activator